4 Stocks Underperforming Today In The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 12 points (0.1%) at 14,943 as of Thursday, Sept. 5, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,432 issues advancing vs. 1,453 declining with 120 unchanged.

The Health Services industry currently sits up 0.4% versus the S&P 500, which is up 0.2%. A company within the industry that fell today was Smith & Nephew ( SNN), up 0.7%. Top gainers within the industry include MiMedx Group ( MDXG), up 20.6%, WellCare Health Plans ( WCG), up 3.5%, Mindray Medical International ( MR), up 2.5%, DaVita HealthCare Partners ( DVA), up 1.9% and ResMed ( RMD), up 1.8%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is down $0.94 (-2.9%) to $31.84 on average volume. Thus far, 153,563 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 206,900 shares. The stock has ranged in price between $31.74-$32.10 after having opened the day at $31.97 as compared to the previous trading day's close of $32.78.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $19.7 billion and is part of the health care sector. Shares are down 4.4% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Grifols ( GRFS) is down $0.23 (-0.8%) to $30.39 on heavy volume. Thus far, 281,040 shares of Grifols exchanged hands as compared to its average daily volume of 347,500 shares. The stock has ranged in price between $30.00-$30.70 after having opened the day at $30.70 as compared to the previous trading day's close of $30.62.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $10.5 billion and is part of the health care sector. Shares are up 18.0% year to date as of the close of trading on Wednesday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Opko Health ( OPK) is down $0.19 (-2.2%) to $8.41 on heavy volume. Thus far, 3.3 million shares of Opko Health exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $8.36-$8.67 after having opened the day at $8.59 as compared to the previous trading day's close of $8.60.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.1 billion and is part of the health care sector. Shares are up 78.8% year to date as of the close of trading on Wednesday. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Intuitive Surgical ( ISRG) is down $2.92 (-0.8%) to $384.40 on light volume. Thus far, 110,025 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 580,400 shares. The stock has ranged in price between $384.08-$388.76 after having opened the day at $388.17 as compared to the previous trading day's close of $387.32.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $15.3 billion and is part of the health care sector. Shares are down 21.5% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Intuitive Surgical a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Intuitive Surgical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Mining and Resources Lead Europe's Benchmarks Lower

Mining and Resources Lead Europe's Benchmarks Lower

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Here's What's Boosting European Benchmarks

Here's What's Boosting European Benchmarks

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space